The 57% uORR in pancreatic cancer and the accelerated registration-enabling trial plans are strong positive catalysts for ERAS. However, this is an early-stage, single-arm Phase 1 dataset with limited patients (N=7 at RDE). Monitor for additional confirmatory data, particularly the initiation of the planned Phase 3 trials and the H1 2027 data readouts.
Drugs in focus
ERAS drug pipeline →ERAS-0015
◆ Mixed Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- ~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
- Next catalyst
- None dated
What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $19.50entry
- T+1 · 4mo ago +9.03%α +8.63% · $21.26
- T+5 · 4mo ago −3.49%α −2.19% · $18.82
- T+20 · 3mo ago −6.10%α −8.59% · $18.31
- T+60 · 6w ago −27.59%α −30.97% · $14.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca reported encouraging preliminary Phase 1 data for ERAS-0015, its pan-RAS molecular glue, showing a 57% unconfirmed overall response rate (uORR) at 8 weeks in 2L+ KRAS G12X pancreatic cancer at the 32 mg QD recommended dose. The company outlined accelerated development plans including a potentially registration-enabling trial in lung cancer in H1 2027 and a Phase 3 pancreatic cancer trial in 2027, which for an early-stage biotech is a significant positive catalyst.
Key Facts
- 57% uORR8wk in 2L+ KRAS G12X pancreatic cancer at RDE of 32 mg QD (N=7).
- Median relative dose intensity of 100% at both 24 mg QD and 32 mg QD.
- No DLTs observed; therapy generally well-tolerated with no discontinuations due to TRAEs.
- First dose escalation combination cohort of ERAS-0015 (16 mg) with panitumumab cleared without DLTs.
- Plan to initiate potentially registration-enabling trial in 2L+ NSCLC in H1 2027.
- Plan to initiate Phase 3 pivotal trial in 1L pancreatic cancer in 2027.
- Additional ERAS-0015 monotherapy and combination data expected in H1 2027.
Financial Impact
Early-stage biotech with no disclosed revenue; the Phase 1 update and registration-enabling plans represent a transformative pipeline catalyst for a company with a $5.8B market cap.
Risk Factors
- Early Phase 1 data with small sample size (N=7 at RDE); response rates may change with more patients.
- Unconfirmed responses may not all convert to confirmed partial responses.
- Potential IP litigation with Revolution Medicines over ERAS-0015 patent infringement allegations.
- Registration-enabling trial plans subject to FDA feedback and may be delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326444 |
Track record
26 reports on ERAS
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers